NEW YORK (GenomeWeb News) – Horizon Discovery announced today that it has licensed non-exclusive rights to Harvard University's intellectual property covering gene-editing technology.

The Cambridge, UK-based firm said the license covers the commercialization of products that utilize Harvard's CRISPR gene-editing technology for research use. CRISPR is an RNA-guided gene editing system that can introduce either a targeted double strand break or single strand nick in the genome of mammalian cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.